Ballantyne AD, Garnock-Jones KP (2013) Dabrafenib: first global approval. Drugs 73(12):1367–1376. https://doi.org/10.1007/s40265-013-0095-2

Article  CAS  PubMed  Google Scholar 

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E et al (2019) Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 381(7):626–636. https://doi.org/10.1056/NEJMoa1904059

Article  CAS  PubMed  Google Scholar 

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al (2017) Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 377(19):1813–1823. https://doi.org/10.1056/NEJMoa1708539

Article  CAS  PubMed  Google Scholar 

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. https://doi.org/10.1016/S0140-6736(12)60868-X

Article  CAS  PubMed  Google Scholar 

Gavric AU, Ocvirk J, Mekjavic PJ (2018) Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib. Radiol Oncol 52(2):213–219. https://doi.org/10.2478/raon-2018-0002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bloch-Michel E, Nussenblatt RB (1987) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234–235. https://doi.org/10.1016/s0002-9394(14)74235-7

Article  CAS  PubMed  Google Scholar 

Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652. https://doi.org/10.1016/s0002-9394(01)00925-4

Article  CAS  PubMed  Google Scholar 

Mettler C, Monnet D, Kramkimel N, Tréluyer JM, Mouthon L, Brézin A et al (2021) Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database. Ophthalmology 128(12):1748–1755. https://doi.org/10.1016/j.ophtha.2021.05.008

Article  PubMed  Google Scholar 

Dimitriou F, Urner-Bloch U, Eggenschwiler C, Mitsakakis N, Mangana J, Dummer R, Urner M (2021) The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer 144:215–223. https://doi.org/10.1016/j.ejca.2020.11.027

Article  CAS  PubMed  Google Scholar 

Chang M, Kuriakose RK, Xu K, Almeida DRP, Chin EK (2021) Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma. Case Rep Ophthalmol 12(2):574–577. https://doi.org/10.1159/000511340

Article  PubMed  PubMed Central  Google Scholar 

Joshi L, Karydis A, Gemenetzi M, Shao EH, Taylor SR (2013) Uveitis as a Result of MAP Kinase Pathway Inhibition. Case Rep Ophthalmol 4(3):279–282. https://doi.org/10.1159/000357060

Article  PubMed  PubMed Central  Google Scholar 

Yeung IY, Popp NA, Chan CC (2015) The role of sex in uveitis and ocular inflammation. Int Ophthalmol Clin 55(3):111–131. https://doi.org/10.1097/IIO.0000000000000072

Article  PubMed  PubMed Central  Google Scholar 

Kaymak NZ, Kaplan AT (2023) Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib/Trametinib Therapy for Cutaneous Malignant Melanoma. Ophthalmic Surg Lasers Imaging Retina 54(8):477–480. https://doi.org/10.3928/23258160-20230524-01

Article  PubMed  Google Scholar 

Boutros A, Schiavi C, Cecchi F, Spagnolo F, Guadagno A, Tanda ET et al (2020) Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient. Front Immunol 11:579523. https://doi.org/10.3389/fimmu.2020.579523

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campos Polo R, GarcíaGuisado D, Rubio Sánchez C, MárquezIvacevich NT (2020) Usefulness of intravitreal dexamethasone implant in the management of «Vogt-Koyanagi-Harada-like syndrome» secondary to map kinase pathway inhibition. Arch Soc Esp Oftalmol (Engl Ed) 95(10):501–506. https://doi.org/10.1016/j.oftal.2020.05.014

Article  CAS  PubMed  Google Scholar 

Lugowska I, Koseła-Paterczyk H, Kozak K, Rutkowski P (2015) Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 8:2251–2259. https://doi.org/10.2147/OTT.S72951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782–789. https://doi.org/10.1016/S1470-2045(12)70269-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12(7):439–444. https://doi.org/10.2217/imt-2019-0206

Article  CAS  PubMed  Google Scholar 

Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol 45(6):735–737. https://doi.org/10.1111/1346-8138.14273

Article  CAS  PubMed  Google Scholar 

Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 158(4):831-837.e2. https://doi.org/10.1016/j.ajo.2014.07.003

Article  CAS  PubMed  Google Scholar 

Wu Q, Niu Y, Chen D, Lin H, Tan M, Hu Y et al (2023) Optical coherence tomography angiography features of retinal artery occlusion before and after intra-arterial thrombolysis. Med Adv 1(2):115–122. https://doi.org/10.1002/med4.14

Article  Google Scholar 

Rohmer E, Scrivener JN, Schissler C, Cribier B, Lenormand C (2019) Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors. Ann Dermatol Venereol 146(11):725–729. https://doi.org/10.1016/j.annder.2019.08.012

Article  CAS  PubMed  Google Scholar 

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF et al (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18(5):1386–1394. https://doi.org/10.1158/1078-0432.CCR-11-2479. (Epub 2011 Dec 12)

Article  CAS  PubMed  Google Scholar 

Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439–2441. https://doi.org/10.1056/NEJMc1111672

Article  CAS  PubMed  Google Scholar 

Joye A, Suhler E (2021) Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 32:574–582. https://doi.org/10.1097/ICU.0000000000000809

Article  PubMed  Google Scholar 

Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S (2015) Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 38:80–84. https://doi.org/10.1097/CJI.0000000000000066

Article  PubMed  PubMed Central  Google Scholar 

Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M (2013) Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 12(11):1033–1038. https://doi.org/10.1016/j.autrev.2013.01.004

Article  CAS  PubMed  Google Scholar